Vaginal Cancer Clinical Trial
Official title:
Lymphoscintigraphy and Selective Lymphatic Mapping in Patients With Invasive Vaginal Cancer
Primary Objectives:
1. Determine the feasibility of using pretreatment lymphoscintigraphy to identify the
sentinel lymph node(s) in patients with vaginal cancer dispositioned to receive
radiation therapy.
2. Determine the feasibility of using preoperative lymphoscintigraphy and intraoperative
lymphatic mapping to identify the sentinel lymph node(s) in patients with vaginal
cancer dispositioned to undergo surgery and bilateral lymph node dissection.
The treatment of vaginal cancer is usually surgical removal of the vaginal tumor with
removal of lymph nodes in the groin and/or pelvis. Patients who are not eligible to receive
surgery usually receive radiation therapy.
Lymph nodes are a common site for the spread of vaginal cancer. Lymphatic mapping has been
used in patients with other types of cancer to identify the "sentinel" lymph node. The
sentinel lymph node is the lymph node believed to be at greatest risk for spread of the
cancer. If the sentinel node does not contain cancer cells, then the remaining lymph nodes
are almost always cancer free.
This research study will find out if the sentinel node concept can be applied to patients
with vaginal cancer. The sentinel lymph node will be identified using a scan called
"lymphoscintigraphy". A very small amount (less than one tenth of a teaspoon) of a
radioactive material is injected around the edge of the tumor in the vagina, followed
immediately by the scan. The scan is done in the Nuclear Medicine Department of M. D.
Anderson before the patient has surgery or begins radiation therapy.
The dose of radiation injected into the vagina is much less than the dose received from a
chest x-ray and therefore there are no special precautions needed after the injection. If
the treatment plan is surgery, a second injection of the radioactive material may be
necessary on the day of the operation because the radiation fades quickly. Patients who
receive radiation therapy will not need a second injection. The radiation oncologist might
use the information collected from the scan to help with treatment planning.
For patients having surgery, a special hand held instrument that measures radioactivity
(similar to a Geiger counter) is used to help identify the location of the sentinel lymph
node before and after the operation begins. Blue dye is also used to find the sentinel node.
This requires the injection of up to a teaspoon of material called Isosulfan Blue around the
tumor in the vagina. This is done while the patient is under anesthesia. The surgeon can
then identify the sentinel node by its color (blue) and by its level of radioactivity (using
the gamma counter).
Patients will be notified of the results of the mapping and lymphoscintigraphy during their
hospitalization or their first clinic visit, depending on whether or not they had surgery.
This is an investigational study. Eighteen patients will take part in this study. All will
be enrolled at M. D. Anderson.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Completed |
NCT02096783 -
Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer
|
N/A | |
Completed |
NCT02058550 -
Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy
|
Phase 1 | |
Completed |
NCT01399658 -
Image-Guided Gynecologic Brachytherapy
|
Phase 2 | |
Completed |
NCT00581646 -
Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance
|
N/A | |
Completed |
NCT03158220 -
Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)
|
Phase 3 | |
Completed |
NCT05372016 -
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
Recruiting |
NCT05743517 -
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
|
N/A | |
Recruiting |
NCT05027776 -
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
|
Phase 3 | |
Recruiting |
NCT05979610 -
Using Reiki Therapy to Improve Symptoms Associated With Brachytherapy in Patients With Gynecological Malignancies
|
Phase 2 | |
Completed |
NCT03956498 -
Impact of a Sexological Follow-up on the Sexual Function in Patients With Cervix or Vaginal Cancer Treated by Radiotherapy and Brachytherapy
|
N/A | |
Recruiting |
NCT04708470 -
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT00551187 -
A Study to Evaluate Tolerability and Immunogenicity of V504 Administered Concomitantly With GARDASIL (V504-001)(COMPLETED)
|
Phase 2 | |
Completed |
NCT00520598 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine in 16 to 26 Year Old Women (V505-001)
|
Phase 2 | |
Terminated |
NCT00669422 -
ChemoFx® PRO - A Post-Market Data Collection Study
|
N/A | |
Completed |
NCT02280811 -
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
|
Phase 2 | |
Completed |
NCT03676101 -
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 1 | |
Active, not recruiting |
NCT00800644 -
Pelvic Fractures and Radiation Therapy for Cervical Cancer
|
||
Recruiting |
NCT06432478 -
3D Printed Custom Applicators for HDR BT (DISCO)
|
N/A | |
Completed |
NCT01703195 -
Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina
|
N/A |